With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Restoring RUNX1 Levels in FPD/AML||University of Washington, Seattle / Marshall Horwitz, MD/PhD||Familial RUNX1 Research Grants||2016||Washington|
|Establishing the Function of Novel MicroRNAs Associated with Resistance and Relapse in Pediatric AML||Fred Hutchinson Cancer Research Center / Vivian Oehler, MD & Soheil Meshinchi, MD/PhD||Innovation Grants||2017||Washington|
|Identification of Resistance Mechanisms and Novel Therapeutic Strategies in Tyrosine Kinase Inhibitor Resistant FLT3/ITD Acute Myeloid Leukemia||Fred Hutchinson Cancer Research Center / Katherine Tarlock, MD||Young Investigator Grants||2014||Washington|
|Advanced Therapeutics for Pediatric Cancer||Seattle Children's Hospital and Regional Medical Center / Julie Park, MD||Phase I/II Infrastructure Grants||2008||Washington|
|Transcriptome Sequencing (RNA-Seq) for Identification of Novel Markers of Disease Outcome and Therapeutic Targets in Acute Myeloid Leukemia||Fred Hutchinson Cancer Research Center / Fabiana Ostronoff, MD||Young Investigator Grants||2012||Washington|
|TrkB Signaling in the Genesis of Murine Neuroblastoma||University of Vermont / Rae Nishi, PhD||Innovation Grants||2007||Vermont|
|Critical Contributions of CRM1 to Leukemogenesis||University of Vermont / Jessica Linda Heath, MD||Young Investigator Grants||2015||Vermont|
|Small Molecule Inhibitors of ERG for Pediatric Leukemia and Sarcoma||University of Virginia, School of Medicine / John Bushweller, PhD||Innovation Grants||2015||Virginia|
|Pharmacogenomics and Drug Screening Lead to a Novel Targeted Therapy with Potent and Specific Activity Against Mouse Models of MYCN-amplified Neuroblastoma||Virginia Commonwealth University / Anthony Faber, MD & Yael Mosse, MD (CHOP)||Innovation Grants||2015||Virginia|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|